A086450 Stock Overview
Produces and sell pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for A086450 from our risk checks.
DongKook Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,580.00 |
| 52 Week High | ₩20,600.00 |
| 52 Week Low | ₩14,140.00 |
| Beta | 0.64 |
| 11 Month Change | -3.30% |
| 3 Month Change | 3.53% |
| 1 Year Change | 11.90% |
| 33 Year Change | -16.68% |
| 5 Year Change | 10.43% |
| Change since IPO | 254.88% |
Recent News & Updates
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Investors Are Less Pessimistic Than Expected
Aug 07
These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well
May 29Recent updates
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Investors Are Less Pessimistic Than Expected
Aug 07These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well
May 29We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt
May 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 06How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?
Mar 15The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?
Feb 28DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?
Feb 14
DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly
Feb 01DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 19The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio
Jan 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting
Dec 21What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?
Dec 08The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It
Nov 23Shareholder Returns
| A086450 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.5% | -8.8% | -6.0% |
| 1Y | 11.9% | 9.9% | -4.4% |
Return vs Industry: A086450 exceeded the KR Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: A086450 exceeded the KR Market which returned -4.4% over the past year.
Price Volatility
| A086450 volatility | |
|---|---|
| A086450 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A086450 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086450's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 1,116 | Heung-Ju Oh | www.dkpharm.co.kr |
DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, and cosmetics. Its pipeline includes DKF-310, which is in preclinical trials for the treatment of dementia; DKM-413, used for anesthetic; DKF-361, used to treat hypertension; DKF-325, an anticoagulant; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, that is in clinical studies, indicated for benign prostatic hyperplasia; DKF-340, a nonsteroidal anti-inflammatory drugs; DKM-415, indicated for synovial fluid replacement; DKF-334 and DKF-335 to treat osteoporosis; and DKF-363, for treatment of respiratory inflammation.
DongKook Pharmaceutical Co., Ltd. Fundamentals Summary
| A086450 fundamental statistics | |
|---|---|
| Market cap | ₩772.96b |
| Earnings (TTM) | ₩54.48b |
| Revenue (TTM) | ₩764.67b |
14.2x
P/E Ratio1.0x
P/S RatioIs A086450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086450 income statement (TTM) | |
|---|---|
| Revenue | ₩764.67b |
| Cost of Revenue | ₩337.35b |
| Gross Profit | ₩427.33b |
| Other Expenses | ₩372.85b |
| Earnings | ₩54.48b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.24k |
| Gross Margin | 55.88% |
| Net Profit Margin | 7.12% |
| Debt/Equity Ratio | 10.4% |
How did A086450 perform over the long term?
See historical performance and comparison